New strategy to distinguish clonal origin of RHCC/MHCC between intrahepatic metastasis and multicentric occurrence

Abstract

Hepatocellular carcinoma (HCC) is a kind of malignancy with high potential of metastasis and multicentric occurrence. The treatment of recurrent hepatocellular carcinoma (RHCC) and multinodular hepatocellular carcinoma (MHCC) is always a nodus because of the diverse clonal origin of RHCC/MHCC. Theoretically, the RHCC/MHCC can originate from intrahepatic metastasis (IM type) or multicentric occurrence (MO type). Our previous study proposed that there are at least 6 subtypes of clonal origin patterns in RHCC. RHCC and MHCC with different clonal origins have variant biological behaviors, clinical prognosis as well as treatment strategy. Generally speaking, patients with IM type HCC have a poorer prognosis compared with those with MO type HCC. Therefore, it is essential to emphasize the distribution of the clonal origin in HCC in order to determine the choice of clinical treatment. Undoubtedly, the detection of clonal origin pattern will become a promising breakthrough in the molecular pathological diagnosis of HCC. We should attach more attention to the establishment of a standardized molecular pathological clonal origin detection method and a new stratification of clinical treatment choice for RHCC/MHCC in future.

Keywords

Hepatocellular carcinoma / clonal origin / molecular pathology / recurrent hepatocellular carcinoma / multinodular hepatocellular carcinoma / intrahepatic metastasis / multicentric occurrence

References

[1] Chen W,Baade PD,Zeng H,Jemal A,He J.Cancer statistics in China, 2015..Cancer J Clin2016;66:115-32

[2] Bruix J,Mazzaferro V.Hepatocellular carcinoma: clinical frontiers and perspectives..Gut2014;63:844-55 PMCID:PMC4337888

[3] Belghiti J,Farges O,Fekete F.Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis..Ann Surg1991;214:114-7 PMCID:PMC1358509

[4] Imamura H,Miyagawa Y,Shimada R,Makuuchi M.Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma..Br J Surg1999;86:1032-8

[5] Grazi GL,Pierangeli F,Cescon M,Mazziotti A.Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value..Ann Surg2001;234:71-8 PMCID:PMC1421950

[6] Poon RT,Ng IO,Liu CL.Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma..Cancer2000;89:500-7

[7] Mise Y,Shindoh J,Aoki T,Sugawara Y,Kokudo N.The feasibility of third or more repeat hepatectomy for recurrent hepatocellular carcinoma..Ann Surg2015;262:347-57

[8] Giannini EG,Ciccarese F,Rapaccini GL,Benvegnu L,Zoli M,Chiaramonte M.Prognosis of untreated hepatocellular carcinoma..Hepatology2015;61:184-90

[9] Liu G,Li J,Lu L,Yan Z,Lau WY,Shen F.Changes in serum alpha fetoprotein in patients with recurrent hepatocellular carcinoma following hepatectomy..J Gastroenterol Hepatol2015;30:1405-11

[10] Hou YF,Yang JY,Xu MQ,Li B.Microvascular invasion patterns affect survival in hepatocellular carcinoma patients after second hepatectomy..J Surg Res2016;200:82-90

[11] Chen R,Ge N,Wang Y,Wang Y,Ren Z.Transarterial chemoembolization versus radiofrequency ablation for recurrent hepatocellular carcinoma after resection within Barcelona clinic liver cancer stage 0/A: a retrospective comparative study..J Vasc Interv Radiol2016;27:1829-36

[12] Sun WC,Liang HL,Chen YC,Lin HS,Hsu PI,Cheng JS.Comparison of repeated surgical resection and radiofrequency ablation for small recurrent hepatocellular carcinoma after primary resection..Oncotarget2017;8:104571-81 PMCID:PMC5732828

[13] Forner A,Bruix J.Hepatocellular carcinoma..Lancet2018;391:1301-14

[14] Cong WM,Chen J,Zhu YY,Chen J.Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update..World J Gastroenterol2016;22:9279-87 PMCID:PMC5107692

[15] Cong WM.New insights into molecular diagnostic pathology of primary liver cancer: advances and challenges..Cancer letters2015;368:14-9

[16] Fialkow PJ,Yoshida A.Clonal origin of chronic myelocytic leukemia in man..Proc Natl Acad Sci1967;58:1468-71 PMCID:PMC223947

[17] Fialkow PJ,Gartler SM.Clonal origin for individual Burkitt tumours..Lancet1970;1:384-6

[18] Van Etten JL.Clonal origin and spread of metastatic prostate cancer..Endocr Relat Cancer2016;23:R207-17 PMCID:PMC4895916

[19] Begg CB,Carniello JV,Giri D,Schizas M,Andrade VP,Seshan VE.Clonal relationships between lobular carcinoma in situ and other breast malignancies..Breast Cancer Res2016;18:66 PMCID:PMC4918003

[20] Baker AM,Wright NA.Pre-tumour clones, periodic selection and clonal interference in the origin and progression of gastrointestinal cancer: potential for biomarker development..J Pathol2013;229:502-14

[21] Castellarin M,Zeng T,Mayo M,Webb JR,Nelson BH.Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease..J Pathol2013;229:515-24

[22] Shin K,Odegaard JI,Kawano S,Beachy PA.Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma..Nature Cell Biol2014;16:469-78 PMCID:PMC4196946

[23] Fialkow PJ.Clonal origin of human tumors..Rev Cancer1976;458:283-321

[24] Nomoto S,Inokawa Y,Kodera Y.Management of hepatocellular carcinoma should consider both tumor factors and background liver factors..Hepatobil Surg Nutr2014;3:82-5 PMCID:PMC3999425

[25] Feng LH,Lau WY,Zhu YY,Lin YX,Wu MC.Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma..J Cancer Res Clin Oncol2017;143:293-303

[26] Cong WM,Zhu YY.Cong WM.Malignant tumors of the liver and intrahepatic bile ducts..Surgical pathology of hepatobiliary tumors2017;SingaporeSpringer Nature Singapore145-8

[27] Massague J.Metastatic colonization by circulating tumour cells..Nature2016;529:298-306 PMCID:PMC5029466

[28] McGranahan N.Clonal heterogeneity and tumor evolution: past, present, and the future..Cell2017;168:613-28

[29] Lasorella A,Iavarone A.The ID proteins: master regulators of cancer stem cells and tumour aggressiveness..Nature Rev Cancer2014;14:77-91

[30] Moeini A,Zhang Z,Stueck A,Montal R,Martinez-Quetglas I,Hao K,Thung SN,Llovet JM.Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity..J Hepatol2017;66:952-61

[31] Xue R,Guo H,Su Z,Qi L,Li Q,Xie XS,Zhang N.Variable intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma..Gastroenterology2016;150:998-1008

[32] Duan M,Cui S,Zhang S,Shi J,Wang X,Cao Y,Zhang X,Fan J,Gao Q.Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing..Cell Res2018;28:359-73

[33] Wang B,Lau WY,Dong H,Jin GZ,Wu MC.Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: a new strategy for hepatic surgery..J Am Coll Surg2013;217:1054-62

[34] Wang Z,Shou D,Gu X,Teng D.Clonal origin of hepatocellular carcinoma and recurrence after liver transplantation..Ann Transplant2016;21:484-90

[35] de'Angelis N,Carra MC.Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review..World J Gastroenterol2015;21:11185-98 PMCID:PMC4607916

[36] Choi SI,Kim BH,Park SS,Park JW.A model predicting survival of patients with recurrent or progressive hepatocellular carcinoma: the MORE score..J Gastroenterology Hepatol2017;32:651-8

[37] Bodzin AS,Markovic D,Busuttil RW.Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics..Ann Surg2017;266:118-25

[38] Nagai S,Kubal CA,Fridell JA,Maluccio MA.Prognosis after recurrence of hepatocellular carcinoma in liver transplantation: predictors for successful treatment and survival..Clin Transplant2015;29:1156-63

[39] Na GH,You YK.Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation..World J Gastroenterol2016;22:5790-9 PMCID:PMC4932214

[40] Muaddi H,Beecroft R,Moulton CA,Selzner M,McGilvray ID,Grant DR,Greig PD,Cleary SP.Liver transplantation is equally effective as a salvage therapy for patients with hepatocellular carcinoma recurrence following radiofrequency ablation or liver resection with curative intent..Ann Surg Oncol2018;25:991-9

[41] Perea Del Pozo E,Sendin Matin M,Alamo Martinez JM,Marin Gomez LM,Gomez Bravo MA.Recurrent hepatocellular carcinoma after liver transplantation: analysis of risk factors..Transplant Proc2016;48:2990-3

[42] Erridge S.Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma..Br J Surg2017;104:1433-42

[43] Gavriilidis P,Azoulay D.Survival following redo hepatectomy vs radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis..HPB (Oxford).2017;19:3-9

[44] Wang DY,Qi XS,Chen X,Chen J,Guo XZ.Hepatic re-resection versus transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma after initial resection: a systematic review and meta-analysis..Asian Pac J Cancer Prev2015;16:5573-8

[45] Huang J,Wu H,Liao M.Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation?.J Surg Res2016;200:122-30

[46] Zhang X,Wen T.Outcomes of salvage liver transplantation and re-resection/radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma: a new surgical strategy based on recurrence pattern..Dig Dis Sci2018;63:502-14

[47] Hao S,Chen S,Wan C.Distinct recurrence risk factors for intrahepatic metastasis and multicenter occurrence after surgery in patients with hepatocellular carcinoma..J Gastrointest Surg2017;21:312-20

[48] Zhang X,Wen T,Li B,Wang W,Lu W.Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern..Eur J Gastroenterol Hepatol2015;27:933-40

[49] Chen PJ,Lai MY,Huang GT,Sheu JC,Hsu HC.Clonal origin of recurrent hepatocellular carcinomas..Gastroenterology1989;96:527-9

[50] Yamamoto T,Kudo M,Arakawa Y.Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA..Hepatology1999;29:1446-52

[51] Liang XH.Clonal origin of intrahepatic recurrence after resection of hepatocellular carcinoma..Chin J Oncol1991;13:2-4

[52] Kuo SH,Chen DS,Lin CC.DNA clonal heterogeneity of hepatocellular carcinoma demonstrated by Feulgen-DNA analysis..Liver1987;7:359-63

[53] Nagasue N,Chang YC,Kimoto T,Nakamura T.DNA ploidy pattern in synchronous and metachronous hepatocellular carcinomas..J Hepatol1992;16:208-14

[54] Hsu HC,Lai PL,Chen DS,Slagle BL.Allelotype and loss of heterozygosity of p53 in primary and recurrent hepatocellular carcinomas. A study of 150 patients..Cancer1994;73:42-7

[55] Shi JY,Duan M,Yang LX,Wang XY,Deng M,Ke AW,Fan J,Wang J,Gao Q.Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity..Oncotarget2016;7:2867-77

[56] Cong WM. The status and thinking of clinicopathological study of multiple nodular hepatocellular carcinoma. Available from: http://oversea.cnki.net/kcms/detail/detail.aspxrecid=&FileName=ZGKA201510001011&DbName=CPFD2016&DbCode=CPFD [Last accessed on 24 May 2018].

[57] Llovet JM,Bruix J.Prognosis of hepatocellular carcinoma: the BCLC staging classification..Semin Liver Dis1999;19:329-38

[58] European Association for the Study of the Liver.EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma..J Hepatol2012;56:908-43

[59] Bruix J.Management of hepatocellular carcinoma: an update..Hepatology2011;53:1020-2 PMCID:PMC3084991

[60] Wada H,Noda T,Yamada D,Tomokuni A,Kawamoto K,Marubashi S,Nagano H,Mori M.Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple hepatocellular carcinoma..Surgery2016;160:1227-35

[61] Zhong JH,Gong WF,Ma L,Peng T,Li LQ.Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma..Ann Surg2014;260:329-40

[62] Torzilli G,Kokudo N,Capussotti L,Vauthey JN,De Santibanes E,Morenghi E.A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group..Ann Surg2013;257:929-37

[63] Qin HG,Xiang BD,Peng NF,Yuan WP,Ma L.Comparison of the prognosis after hepatic resection for patients with Barcelona Clinical Liver Cancer stage B hepatocellular carcinoma..Natl Med J China2016;96:3384-8

[64] Zhou YD,Cui YL,Li Q.The indications for hepatectomy for multinodular hepatocellular carcinoma: experience from a single institution..Dig Surg2015;32:82-9

[65] Ciria R,Gallardo AB,Pleguezuelo M,Luque A,Espejo JJ,Montero JL,Brice-o J.Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: modern surgical resection as a feasible alternative to transarterial chemoemolization..Eur J Surg Oncol2015;41:1153-61

[66] Guo Z,Hu B,Li LQ.Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma within Milan criteria: a propensity score matching analysis..Medicine2017;96:e8933 PMCID:PMC5758128

[67] Huang L,Yan J,Liu C,Wu M.Early recurrence after curative resection in oligonodular hepatocellular carcinoma..Hepatogastroenterology2013;60:28-31

[68] Nojiri K,Takeda K,Matsuyama R,Kumamoto T,Endo I.The efficacy of liver resection for multinodular hepatocellular carcinoma..Anticancer Res2014;34:2421-6

[69] Govindarajan S,Valinluck B.Clonal origin of hepatitis B virus-associated hepatocellular carcinoma..Hum Pathol1988;19:403-5

[70] Aoki N.State of hepatitis B viral genomes in cirrhotic and hepatocellular carcinoma nodules..Mol Biol Med1989;6:395-408

[71] Nomoto S,Kato K,Kasuya H,Kanazumi N,Nakao A.Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma..Br J Cancer2007;97:1260-5 PMCID:PMC2360457

[72] Sirivatanauksorn Y,Bhattacharya S,Dhillon AP,Williamson RC.Genomic heterogeneity in synchronous hepatocellular carcinomas..Gut1999;45:761-5 PMCID:PMC1727708

[73] Nomoto S,Koshikawa K,Sidransky D.Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma..Clin Cancer Res2002;8:481-7

[74] Okuda T,Kubo S,Fujita M,Haba T,Kinoshita H.Clonal analysis of hepatocellular carcinoma and dysplastic nodule by methylation pattern of X-chromosome-linked human androgen receptor gene..Cancer Letters2001;164:91-6

[75] Hsu HC,Chen JY,Lee PH.Clonality and clonal evolution of hepatocellular carcinoma with multiple nodules..Hepatology1991;13:923-8

[76] Tsuda H,Sakamoto M.Different pattern of chromosomal allele loss in multiple hepatocellular carcinomas as evidence of their multifocal origin..Cancer Res1992;52:1504-9

[77] Hui AM,Imamura H,Ishii K,Makuuchi M.Heterogeneity of DNA content in multiple synchronous hepatocellular carcinomas..Br J Cancer1997;76:335-9 PMCID:PMC2224061

[78] Furuta M,Fujimoto A,Yasukawa S,Arihiro K,Wardell CP,Tanaka H,Maejima K,Tokunaga N,Abe T,Ohdan H,Kubo M,Miyano S,Yamaue H.Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors..J Hepatol2017;66:363-73

[79] Lin DC,Dinh HQ,Lin L,Ding LW,Berman BP,Yin D.Genomic and epigenomic heterogeneity of hepatocellular carcinoma..Cancer Res2017;77:2255-65 PMCID:PMC5413372

[80] Ng IO,Poon RT,Lee JM.Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis..J Pathol2003;199:345-53

[81] Hodges KB,Saxena R,Zhang S,Montironi R,Cheng L.Clonal origin of multifocal hepatocellular carcinoma..Cancer2010;116:4078-85

[82] Zhao Q,Dong H,Wu MC.Hepatocellular carcinoma and hepatic adenocarcinosarcoma in a patient with hepatitis B virus-related cirrhosis..Semin Liver Dis2010;30:107-12

[83] Zhao Q,Lu XY,Gu YJ,Cong WM.Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study..Chin J Cancer2016;35:82 PMCID:PMC4995671